138 related articles for article (PubMed ID: 34973392)
1. Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase.
Haitani T; Kobayashi M; Koyasu S; Akamatsu S; Suwa T; Onodera Y; Nam JM; Nguyen PTL; Menju T; Date H; Ogawa O; Harada H
Cancer Lett; 2022 Mar; 528():76-84. PubMed ID: 34973392
[TBL] [Abstract][Full Text] [Related]
2. Mutual Balance of Histone Deacetylases 1 and 2 and the Acetyl Reader ATAD2 Regulates the Level of Acetylation of Histone H4 on Nascent Chromatin of Human Cells.
Lazarchuk P; Hernandez-Villanueva J; Pavlova MN; Federation A; MacCoss M; Sidorova JM
Mol Cell Biol; 2020 Apr; 40(9):. PubMed ID: 32015101
[TBL] [Abstract][Full Text] [Related]
3. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication.
Koo SJ; Fernández-Montalván AE; Badock V; Ott CJ; Holton SJ; von Ahsen O; Toedling J; Vittori S; Bradner JE; Gorjánácz M
Oncotarget; 2016 Oct; 7(43):70323-70335. PubMed ID: 27612420
[TBL] [Abstract][Full Text] [Related]
4. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain.
Evans CM; Phillips M; Malone KL; Tonelli M; Cornilescu G; Cornilescu C; Holton SJ; Gorjánácz M; Wang L; Carlson S; Gay JC; Nix JC; Demeler B; Markley JL; Glass KC
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502039
[TBL] [Abstract][Full Text] [Related]
5. HIF1α-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia.
Nayak A; Roy AD; Rout N; Singh SP; Bhattacharyya A; Roychowdhury A
Biochem Biophys Res Commun; 2020 Mar; 523(4):916-923. PubMed ID: 31959473
[TBL] [Abstract][Full Text] [Related]
6. Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains.
Phillips M; Malone KL; Boyle BW; Montgomery C; Kressy IA; Joseph FM; Bright KM; Boyson SP; Chang S; Nix JC; Young NL; Jeffers V; Frietze S; Glass KC
J Med Chem; 2024 May; 67(10):8186-8200. PubMed ID: 38733345
[TBL] [Abstract][Full Text] [Related]
7. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.
Gay JC; Eckenroth BE; Evans CM; Langini C; Carlson S; Lloyd JT; Caflisch A; Glass KC
Proteins; 2019 Feb; 87(2):157-167. PubMed ID: 30520161
[TBL] [Abstract][Full Text] [Related]
8. Structure of the human ATAD2 AAA+ histone chaperone reveals mechanism of regulation and inter-subunit communication.
Cho C; Ganser C; Uchihashi T; Kato K; Song JJ
Commun Biol; 2023 Sep; 6(1):993. PubMed ID: 37770645
[TBL] [Abstract][Full Text] [Related]
9. The ATAD2 bromodomain binds different acetylation marks on the histone H4 in similar fuzzy complexes.
Langini C; Caflisch A; Vitalis A
J Biol Chem; 2017 Oct; 292(40):16734-16745. PubMed ID: 28798233
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.
Wang XL; Wang S; Wu ZZ; Yang QC; Li H; Xiong HG; Wan SC; Sun ZJ
Int J Med Sci; 2020; 17(11):1598-1609. PubMed ID: 32669963
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.
Lee PWT; Koseki LR; Haitani T; Harada H; Kobayashi M
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730681
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Promoting ATAD2 and Its Preclinical Challenges.
Liu H; Wen Q; Yan S; Zeng W; Zou Y; Liu Q; Zhang G; Zou J; Zou X
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008934
[No Abstract] [Full Text] [Related]
13. MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway.
Wang AQ; Lv M; Xu YH; Xie PM; Dong YY
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9860-9868. PubMed ID: 33090389
[TBL] [Abstract][Full Text] [Related]
14. Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling.
Wang JH; Yu TT; Li Y; Hao YP; Han L; Xu KY; Xu P
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6055-6063. PubMed ID: 32572920
[TBL] [Abstract][Full Text] [Related]
15. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.
Fu J; Zhang J; Chen X; Liu Z; Yang X; He Z; Hao Y; Liu B; Yao D
Theranostics; 2023; 13(2):787-809. PubMed ID: 36632213
[TBL] [Abstract][Full Text] [Related]
16. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
17. ATAD2 drives colorectal cancer progression by regulating TRIM25 expression via a positive feedback loop with E2F transcriptional factors.
Tong Y; Li J; Peng M; Qian Q; Shi W; Chen Z; Liu B
Biochem Biophys Res Commun; 2022 Feb; 594():146-152. PubMed ID: 35085891
[TBL] [Abstract][Full Text] [Related]
18. Silencing of ATPase family AAA domain-containing protein 2 inhibits migration and invasion of colorectal cancer cells.
Hong S; Bi M; Yan Z; Sun D; Ling L; Zhao C
Neoplasma; 2016; 63(6):846-855. PubMed ID: 27565322
[TBL] [Abstract][Full Text] [Related]
19. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
20. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
